CYCC
- Cyclacel Pharmaceuticals, Inc.
()
Overview
Company Summary
Cyclacel Pharmaceuticals, Inc. (CYCC) is a biopharmaceutical company that focuses on the development and commercialization of innovative drugs for the treatment of various types of cancer. The company utilizes its expertise in cell cycle control biology to develop targeted therapies that aim to disrupt the growth and division of cancer cells.
Cyclacel Pharmaceuticals employs a unique approach to cancer treatment by targeting specific proteins and pathways involved in cell cycle regulation. Their drug development programs primarily focus on two main areas: the cyclin-dependent kinases (CDKs) and the polo-like kinases (PLKs). CDKs and PLKs play crucial roles in cell division, and by targeting these proteins, Cyclacel aims to inhibit the uncontrolled growth and proliferation of cancer cells.
One of the key drug candidates in Cyclacel's pipeline is Sapacitabine, an oral chemotherapy agent that targets CDKs. Sapacitabine has shown promising results in clinical trials for various types of cancer, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The company is also developing CYC065, a PLK inhibitor, which has potential applications in multiple cancer types.
Cyclacel Pharmaceuticals collaborates with leading academic institutions, research organizations, and pharmaceutical companies to advance their drug development programs. They also actively seek partnerships and licensing opportunities to maximize the commercial potential of their drug candidates.
Overall, Cyclacel Pharmaceuticals is dedicated to discovering and developing innovative therapies that have the potential to improve patient outcomes and address the unmet medical needs in various cancer types.